Lamin B1 is a potential therapeutic target and prognostic biomarker for hepatocellular carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Raoul JL, Forner A, Bolondi L, et al. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev. 2019;72:28–36.
   PubMed Web of Science ®Google Scholar
• Chen L, Sun J, Yang X. Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: current status. Cancer Lett. 2016;370(1):78–84.
   PubMed Web of Science ®Google Scholar
• Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1–61.
   PubMed Web of Science ®Google Scholar
• Ghavimi S, Apfel T, Azimi H, et al. Management and treatment of hepatocellular carcinoma with immunotherapy: a review of current and future options. J Clin Transl Hepatol. 2020;8(2):168–176.
   PubMed Web of Science ®Google Scholar
• Chen S, Cao Q, Wen W, et al. Targeted therapy for hepatocellular carcinoma: challenges and opportunities. Cancer Lett. 2019;460:1–9.
   PubMed Web of Science ®Google Scholar
• Tang W, Chen Z, Zhang W, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020;5(1):87.
   PubMed Web of Science ®Google Scholar
• Camps J, Erdos MR, Ried T. The role of lamin B1 for the maintenance of nuclear structure and function. Nucleus. 2015;6(1):8–14.
   PubMed Web of Science ®Google Scholar
• Hutchison CJ. B-type lamins in health and disease. Semin Cell Dev Biol. 2014;29:158–163.
   PubMed Web of Science ®Google Scholar
• Dechat T, Pfleghaar K, Sengupta K, et al. Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin. Genes Dev. 2008;22(7):832–853.
   PubMed Web of Science ®Google Scholar
• Brady GF, Kwan R, Bragazzi Cunha J, et al. Lamins and lamin-associated proteins in gastrointestinal health and disease. Gastroenterology. 2018;154(6):1602–1619.
   PubMed Web of Science ®Google Scholar
• Izdebska M, Gagat M, Grzanka A. Overexpression of lamin B1 induces mitotic catastrophe in colon cancer LoVo cells and is associated with worse clinical outcomes. Int J Oncol. 2017;52(1):89–102.
   PubMed Web of Science ®Google Scholar
• Yu ZY, Jiang XY, Zhao RR, et al. Lamin B1 deficiency promotes malignancy and predicts poor prognosis in gastric cancer. Neoplasma. 2020;67(6):1303.
   PubMed Web of Science ®Google Scholar
• Li L, Du Y, Kong X, et al. Lamin B1 is a novel therapeutic target of betulinic acid in pancreatic cancer. Clin Cancer Res. 2013;19(17):4651–4661.
   PubMed Web of Science ®Google Scholar
• Radspieler MM, Schindeldecker M, Stenzel P, et al. Lamin-B1 is a senescence-associated biomarker in clear-cell renal cell carcinoma. Oncol Lett. 2019;18(3):2654–2660.
   PubMed Web of Science ®Google Scholar
• Sun S, Xu MZ, Poon RT, et al. Circulating Lamin B1 (LMNB1) biomarker detects early stages of liver cancer in patients. J Proteome Res. 2010;9(1):70–78.
   PubMed Web of Science ®Google Scholar
• Wong KF, Luk JM. Discovery of lamin B1 and vimentin as circulating biomarkers for early hepatocellular carcinoma. Methods Mol Biol. 2012;909:295–310.
   PubMedGoogle Scholar
• Tellapuri S, Sutphin PD, Beg MS, et al. Staging systems of hepatocellular carcinoma: a review. Indian J Gastroenterol. 2018;37(6):481–491.
   PubMed Web of Science ®Google Scholar
• Burkhart RA, Pawlik TM. Staging and prognostic models for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control. 2017;24(3):544013179.
   Web of Science ®Google Scholar
• Giannini EG, Bucci L, Garuti F, et al. Patients with advanced hepatocellular carcinoma need a personalized management: a lesson from clinical practice. Hepatology. 2018;67(5):1784–1796.
   PubMed Web of Science ®Google Scholar
• Golfieri R, Bargellini I, Spreafico C, et al. Patients with Barcelona clinic liver cancer stages b and c hepatocellular carcinoma: time for a subclassification. Liver Cancer. 2019;8(2):78–91.
   PubMed Web of Science ®Google Scholar
• Zhou W, Zhang Y, Zhang S, et al. Absent in melanoma 1-like (AIM1L) serves as a novel candidate for overall survival in hepatocellular carcinoma. Bioengineered. 2021;12(1):2750–2762.
   PubMed Web of Science ®Google Scholar
• Ouyang G, Yi B, Pan G, et al. A robust twelve-gene signature for prognosis prediction of hepatocellular carcinoma. Cancer Cell Int. 2020;20:207.
   PubMed Web of Science ®Google Scholar
• Long J, Zhang L, Wan X, et al. A four‐gene‐based prognostic model predicts overall survival in patients with hepatocellular carcinoma. J Cell Mol Med. 2018;22(12):5928–5938.
   PubMed Web of Science ®Google Scholar
• Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. Bmc Bioinformatics. 2008;9(1):559.
   PubMed Web of Science ®Google Scholar
• Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. Bmc Bioinformatics. 2013;14:7.
   PubMed Web of Science ®Google Scholar
• Ramos-Vara JA. Principles and Methods of Immunohistochemistry. Methods Mol Biol. 2017;1641:115–128.
   PubMedGoogle Scholar
• Huang Y, Xiang B, Liu Y, et al. LncRNA CDKN2B-AS1 promotes tumor growth and metastasis of human hepatocellular carcinoma by targeting let-7c-5p/NAP1L1 axis. Cancer Lett. 2018;437:56–66.
   PubMed Web of Science ®Google Scholar
• Hung JH, Yang TH, Hu Z, et al. Gene set enrichment analysis: performance evaluation and usage guidelines. Brief Bioinform. 2012;13(3):281–291.
   PubMed Web of Science ®Google Scholar
• Kou YB, Zhang SY, Zhao BL, et al. Knockdown of MMP11 inhibits proliferation and invasion of gastric cancer cells. Int J Immunopathol Pharmacol. 2013;26(2):361–370.
   PubMed Web of Science ®Google Scholar
• Bruix J, Han K, Gores G, et al. Liver cancer: approaching a personalized care. J Hepatol. 2015;62(1):S144–S156.
   PubMedGoogle Scholar
• Lin F, Worman HJ. Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C. J Biol Chem. 1993;268(22):16321–16326.
   PubMed Web of Science ®Google Scholar
• Lin F, Worman HJ. Structural organization of the human gene (LMNB1) encoding nuclear lamin B1. Genomics. 1995;27(2):230–236.
   PubMed Web of Science ®Google Scholar
• Yang SH, Jung H, Coffinier C, et al. Are B-type lamins essential in all mammalian cells? Nucleus. 2011;2(6):562–569.
   PubMed Web of Science ®Google Scholar
• Harborth J, Elbashir SM, Bechert K, et al. Identification of essential genes in cultured mammalian cells using small interfering RNAs. J Cell Sci. 2001;114(Pt 24):4557–4565.
   PubMed Web of Science ®Google Scholar
• Jia Y, Vong JS, Asafova A, et al. Lamin B1 loss promotes lung cancer development and metastasis by epigenetic derepression of RET. J Exp Med. 2019;216(6):1377–1395.
   PubMed Web of Science ®Google Scholar
• Klymenko T, Bloehdorn J, Bahlo J, et al. Lamin B1 regulates somatic mutations and progression of B-cell malignancies. Leukemia. 2018;32(2):364–375.
   PubMed Web of Science ®Google Scholar
• Luo F, Han J, Chen Y, et al. Lamin B1 promotes tumor progression and metastasis in primary prostate cancer patients. Future Oncol. 2021;17(6):663–673.
   PubMed Web of Science ®Google Scholar
• Leverrier-Penna S, Destaing O, Penna A. Insights and perspectives on calcium channel functions in the cockpit of cancerous space invaders. Cell Calcium. 2020;90:102251.
   PubMed Web of Science ®Google Scholar
• Yang L, Qiu J, Xiao Y, et al. AP-2beta inhibits hepatocellular carcinoma invasion and metastasis through Slug and Snail to suppress epithelial-mesenchymal transition. Theranostics. 2018;8(13):3707–3721.
   PubMed Web of Science ®Google Scholar
• Yang A, Zhao Y, Wang Y, et al. Huaier suppresses proliferative and metastatic potential of prostate cancer PC3 cells via downregulation of Lamin B1 and induction of autophagy. Oncol Rep. 2018;39(6):3055–3063.
   PubMed Web of Science ®Google Scholar
• Yang J, Nie J, Ma X, et al. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019;18(1):26.
   PubMed Web of Science ®Google Scholar
• Ma X, Shen M, Hu B, et al. CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis. J Hematol Oncol. 2019;12(1): 37.
   Google Scholar
• Diniz PHC, Silva SDC, Vidigal PVT, et al. Expression of MAPK and PI3K/AKT/mTOR proteins according to the chronic liver disease etiology in hepatocellular carcinoma. J Oncol. 2020;2020:1–9.
   Web of Science ®Google Scholar
• Sueangoen N, Tantiwetrueangdet A, Panvichian R. HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant. Cell Biosci. 2020;10(1):41.
   PubMed Web of Science ®Google Scholar
• Wang W, Ma X, Shi Z, et al. Epidermal growth factor receptor pathway polymorphisms and the prognosis of hepatocellular carcinoma. Am J Cancer Res. 2015;5(1):396–410.
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Esnaola NF, Vauthey JN. Surgical treatment of hepatocellular carcinoma: similar long-term results despite geographic variations. Liver Transpl. 2004;10(2 Suppl 1):S74–S80.
   PubMedGoogle Scholar
• Li L, Wang H. Heterogeneity of liver cancer and personalized therapy. Cancer Lett. 2016;379(2):191–197.
   PubMed Web of Science ®Google Scholar
• Feng Y, Tang X, Li C, et al. ARID1A is a prognostic biomarker and associated with immune infiltrates in hepatocellular carcinoma. Can J Gastroenterol Hepatol. 2022;2022:3163955.
   PubMed Web of Science ®Google Scholar
• Yang Z, Zi Q, Xu K, et al. Development of a macrophages-related 4-gene signature and nomogram for the overall survival prediction of hepatocellular carcinoma based on WGCNA and LASSO algorithm. Int Immunopharmacol. 2021;90:107238.
   PubMed Web of Science ®Google Scholar
• Dai Y, Qiang W, Lin K, et al. An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma. Cancer Immunol Immunother. 2021;70(4):967–979.
   PubMed Web of Science ®Google Scholar